REVIEW ARTICLEUse of direct oral anticoagulants in cerebral venous thrombosis: a systematic reviewSheng, Sena; Nalleballe, Krishinaa; Pothineni, Naga V.b; Sharma, Rohana; Brown, Alizad; Elkhider, Hishama; Ranabothu, Sarithac; Kapoor, Nidhia; Patrice, Kelly-Anna; Onteddu, SanjeevaaAuthor Information aDepartment of Neurology bDepartment of Cardiology cDepartment of Pediatrics dUniversity of Arkansas for Medical Sciences, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA Correspondence to Sen Sheng, MD, PhD, Department of Neurology, University of Arkansas for Medical Sciences, 4301 West Markham Street, Slot 500, Little Rock, AR 72205, USA Tel: +1 501 686 5838; fax: +1 501 320 7277; e-mail: [email protected] Received 14 August, 2019 Revised 20 July, 2020 Accepted 4 August, 2020 Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (www.bloodcoagulation.com). Blood Coagulation & Fibrinolysis: December 2020 - Volume 31 - Issue 8 - p 501-505 doi: 10.1097/MBC.0000000000000958 Buy SDC Metrics Abstract We are here to review the efficacy and safety of direct oral anticoagulants (DOACs) in the treatment of Cerebral Venous Thrombosis (CVT). A search strategy was developed with a research librarian. All published articles including trials, studies, case series, and case reports were reviewed from NCBI/PubMed up to May 2019 by two independent reviewers. A total of 11 studies were identified, which included 70 patients with CVT on DOACs. After 6 months follow-up more than 86.7% of these patients had a good outcome on the Modified Rankin Scale (mRS) of 0--1 at 6 months and no recurrence of venous thromboembolic events (VTE) at 12 months. Recanalization rate at 6 months varied from 55 to 100%. Only two patients had a side effect of minor bleeding because of DOAC usage. Although the current American Heart Association/American Stroke Association and European Stroke Organization guidelines do not endorse the use of DOACs for treatment of CVT because of lack of evidence from large randomized clinical trials, Use of DOACs in CVT appears to be well tolerated and efficacious with favorable outcomes. Further evidence is needed to establish their use in CVT. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.